Tesamorelin is a synthetic peptide analogue of growth hormone-releasing hormone (GHRH), also called growth hormone-releasing factor (GRF). It is distinct from growth hormone itself. [1]
For laboratory and analytical research only. Not for human consumption, medical, diagnostic, therapeutic, or veterinary use.
Identity and research context
GHRH is part of the signaling system that regulates growth hormone secretion. A human study by Stanley and colleagues examined tesamorelin in relation to endogenous growth hormone pulsatility and insulin sensitivity. These are measurements made under a defined study protocol, not specifications for a research vial. [1]
Tesamorelin is also the active ingredient named in Egrifta prescription-drug labeling. The FDA’s 2025 Egrifta WR label records initial U.S. approval in 2010. That approval concerns the labeled drug product; it does not establish equivalence of AlphaGrade research materials to that medicine. [2]
Documentation and lot traceability
Product- or lot-specific documentation may be available depending on the material and lot. Request the current lot’s documentation through Contact. Include the product name and the lot identifier from the label. Check that the document identifies the same material and lot before interpreting its results. A report for another brand or lot does not establish the properties of your material.
For tesamorelin, request the stated chemical form as well as the identity and quantity information. A product name or nominal vial amount does not specify the salt form or replace lot-specific documentation.
AlphaGrade listings
These links identify catalog listings. Check each listing for its current commercial details.
Frequently asked questions
Is tesamorelin the same as growth hormone?
No. Tesamorelin is a GHRH analogue studied for its effects on endogenous growth hormone secretion; growth hormone is a different molecule. [1]
Does a published study verify a particular vial?
No. Published research describes the study material and methods. Product identity and lot documentation must be evaluated separately.
References
- Stanley TL et al. (2011). Human study of tesamorelin, GH pulsatility and insulin sensitivity. J Clin Endocrinol Metab. 96(1):150–158. DOI: 10.1210/jc.2010-1587. Read the primary paper.
- FDA. Egrifta WR prescribing information (2025). Official label.
The cited literature describes the compound or its components. It does not test, certify, or establish the suitability of any material supplied by AlphaGrade.
